Think Global

SERTOFEN tablets

SERTOFEN tablets










Film coated tablets.

Description: round, biconvex, white film coated tablets with score lines at both sides.



A film coated tablet contains:

Active ingredient: dexketoprofen (as dexketoprofen trometamol) 25 mg.

Excipients: microcrystalline cellulose, maize starch, sodium starch glycolate, glycerol distearate.

Composition of Opadry II white film coating: polyvinyl alcohol, titanium dioxide, macrogol, talc.






Nonsteroidal anti-inflammatory drugs. Propionic acid derivatives.




Dexketoprofen is a propionic acid derivative that has an anti-inflammatory, analgesic and antipyretic action. The mechanism of the drug action is based on the inhibition of synthesis of prostaglandins that play an important role in the pathogenesis of pain and inflammation due to the inhibition of cyclooxygenase-1 and cyclooxygenase-2. The analgesic effect starts 30 minutes after the drug administration and its duration is from 4 till 6 hours.


After oral administration of the drug the maximum plasma concentration of dexketoprofen is reached on an average in 30 minutes. The co-administration of meal slows down the drug absorption.

A high level of plasma protein binding (99%) is characteristic for dexketoprofen. Volume of distribution is on an average 0.25 l/kg.

The elimination half-life is 1.65 hours. The main part of the drug is eliminated in urine as metabolites (after glucuronidation). The lengthening of the elimination period on an average up to 48% and the lowering of total body clearance are observed in elderly patients.



- symptomatic treatment of acute and chronic inflammatory and inflammatory-degenerative diseases of locomotor apparatus (including    rheumatoid arthritis, spondyloarthritis, arthrosis, osteochondrosis);

- relief of pain of different genesis  (including posttraumatic or postoperative pain, pain due to bone metastases, pain due to renal colic, radiculitis, neuralgia, dysmenorrhoea, toothache).



Sertofen is administrated orally during a meal, washing down with sufficient quantity of water.

The dosage regimen is established individually depending on the kind and intensity of a pain.

An average recommended single dose is 12.5 mg (1/2 tablet) from 1 till 6 times per day with 4-6 hours interval between the administrations as necessary or 25 mg (1 tablet) from 1 to 3 times per day with 8 hours interval between the administrations.

Maximum daily dose is 75 mg (3 tablets).

In the patients with compromised liver or kidney function and in the elderly patients the administration of Sertofen should be started with lower doses – not more than 50 mg per day.

The drug is not intended for continuous administration: the duration of administration shouldn’t exceed 7 days.



- hypersensitivity to dexketoprofen or other NSAIDs or to any of the excipients comprising the drug;

- disease history of asthma attacks, bronchospasm, acute rhinitis, urticaria or angioneurotic edema appeared due to the administration of the drugs with similar mechanism of action (acetylsalicylic acid and other NSAIDs);

- the patients with active duodenum and gastric ulcer or the presence of repetitive episodes of ulcer disease (two or more episodes);

- gastrointestinal bleedings (including those related with the previous administration of NSAIDs), other active bleedings;

- Crohn's disease, nonspecific ulcerative colitis;

- severe compromise of liver function (10-15 points by Child-Pugh scale);

- severe kidney impairment (creatinine clearance < 50 ml/min);

- bronchial asthma (including the medical history);

- severe heart failure;

- hemorrhagic diathesis or other coagulopathy;

- third trimester of pregnancy and lactation period;

- children and adolescents under 18 years old.



CNS and peripheral nervous system: uncommon – headache, dizziness, insomnia, drowsiness; rarely – paresthesia

Cardiovascular system: rarely – extrasystole, increase in arterial pressure; very rarely – tachycardia, decrease in arterial pressure.

Hemopoietic organ: very rarely – neutropenia, thrombocytopenia.

Respiratory system: rarely – bradypnoea; very rarely – bronchospasm, dyspnea.

Sensory organ: rarely – tinnitus, very rarely – blurred vision.

Digestive system: rarely – nausea, vomiting, abdominal pains, dyspepsia; rarely – erosive-ulcer lesions of gastro-intestinal tract, anorexia.

Urinary system: rarely – polyuria, very rarely – nephritis or nephrotic syndrome.

Metabolism: rarely – hyperglycemia, hypoglycemia, hypertriglyceridemia.

Dermatological reactions: rarely – urticaria, acne, hyperhidrosis; very rarely – severe skin reactions (Stevens-Johnson syndrome, Lyell's syndrome), angioedema, allergic dermatitis, photosensitization.

Systemic disturbance: rarely – fever, fatigability, aseptic meningitis, occurring predominantly in the patients with systemic lupus erythematosus or mixed connective tissue disease, hematological impairments; rarely – anaphylactic shock.



It is necessary to exercise a caution when the drug is prescribed to the elderly patients (older than 65 years old), patients with allergic reactions, with systemic diseases of connective tissue and patients with dyshematopoiesis.

A close medical supervision should be carried out for the patients with gastro-intestinal disturbances or diseases in the anamnesis. If a gastro-intestinal bleeding or an ulcer occurs, the therapy with the drug should be canceled.

As with other NSAIDs, Sertofen can lead to an increase of plasma creatinine and nitrogen concentration. A slight transient augmentation of indices of certain liver function tests, as well as the apparent increase in the AST and ALT levels can be observed during the therapy with dexketoprofen.

The elderly patients have a need in periodical monitoring of liver and kidney function.

It is necessary to control the blood coagulation system in case of co-administration of Sertofen with the drugs influencing the blood coagulability.

Dexketoprofen can mask the symptoms of infectious diseases.

It is necessary to instruct the patients that when side effects appear, as well as if a clinical effect is not observed during 3-5 days of the treatment, they should inform their doctor about this.



During the treatment it is necessary to exercise a caution while driving and performing other kinds of activities involving the heighten attention concentration and the high rate of psychomotor reactions.



Sertofen is contraindicated in the third trimester of pregnancy and during lactation. In the first and second trimester Sertofen can be administrated only in case of need, under the doctor’s recommendation, in minimal doses and during the shortest period of time.



The drug is contraindicated for administration in children and adolescents under 18 years old.



Unadvisable combinations

The co-administration of dexketoprofen with other NSAIDs, including salicylates, increases the risk of gastro-intestinal bleedings.

When co-administered with oral anticoagulants, heparin the drug increases the risk of bleeding development.

NSAIDs increase the blood lithium concentration, thus it is necessary to control this index during the drug administration, the change of dose and after cancelation of NSAIDs.

The co-administration of NSAIDs and methotrexate in high doses (more than 15 mg per week) increases the hematological toxicity of the last one.  

When the drug is co-administered with hydantoins and sulfonamides it is possible the strengthening of the toxic properties of these substances.

Combinations that should be used with caution during administration

Dexketoprofen weakens an antihypertensive action of diuretics, inhibitors of angiotensin-converting-enzyme. 

The co-administration of methotrexate in low doses (less than 15 mg per week) leads to the increase of hematological toxicity of methotrexate due to the lowering of its renal clearance during administration of NSAIDs.

The co-administration with serotonin reuptake inhibitors, oral glucocorticoids increases the risk of the development of the gastro-intestinal bleedings.

NSAIDs strengthens the hypoglycemic action of sulphonylurea due to its displacement from the sited of blood plasma protein binding.

The risk of the development of the gastro-intestinal bleedings is increased when the drug is co-administered with pentoxifylline.

In co-administration with zidovudine there is a risk of the increase of toxic effect on erythrocytes, conditioned by the action on reticulocytes with the developement of severe anemia in a week after the prescribing of NSAIDs. It is necessary to control all cellular elements in blood, including  reticulocytes in 1-2 weeks after the beginning of NSAIDs.

Combinations demanding very special attention

NSAIDs can diminish the hypotensive effect of beta-adrenoblockers that is conditioned by the inhibition of prostaglandins synthesis.

When co-administered with cyclosporine and tacrolimus NSAIDs can strengthen the nephrotoxicity that is conditioned by the effect of renal prostaglandins. It is necessary to control the renal function during combination therapy.

The risk of bleeding development is increased in case of simultaneous administration with thrombolytics.

When co-administrated with probenecids the increase of NSAIDs concentration in blood plasma can occur. It is possible due to the inhibition of renal secretion and/or conjugation with glucuronic acid. It requires the dose correction of NSAIDs.

NSAIDs can cause the increase of blood plasma cardiac glycosid concentration.

Due to the theoretical risk of change of mifepristone efficacy under the influence of prostaglandin synthesis inhibitors, NSAIDs shouldn’t be prescribed earlier than 8-12 days after the cancelation of mifepristone.



Symptoms: nausea, anorexia, abdominal pain, headache, dizziness, disorientation, insomnia.

Treatment: gastric lavage, hemodialysis, symptomatic therapy.



Film coated tablets.

10 tablets in a blister.

1 or 2 blisters together with leaflet in a carton box.



Store in a protected from light place at temperature not exceeding 25°С.

Keep out of reach of children!



3 years from the date of manufacturing.

Do not apply after the shelf-life expiration.



Sold under prescription.



The holder of Marketing Authorization is 


Manufactured by

 “Abdi İbrahim İlaç San. ve Tic. A.Ş.”, Turkey

(Sanayi Mahallesi, Tunç Caddesi No: 3 Esenyurt 34555 / İstanbul).